학술논문

FDA Approval summary: Tucatinib for the treatment of patients with advanced or metastatic HER2-positive breast cancer
Document Type
Article
Source
In: Clinical Cancer Research. (Clinical Cancer Research, 1 March 2021, 27(5):1220-1226)
Subject
Language
English
ISSN
15573265
10780432